News | October 29, 2025
Novartis completes acquisition of Tourmaline Bio
Tourmaline is now an indirect wholly owned subsidiary of Novartis
Tourmaline is now an indirect wholly owned subsidiary of Novartis
Ticagrelor tablets are indicated for reducing the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
Mesalamine suppositories are indicated for the treatment of mildly to moderately active ulcerative proctitis
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
Subscribe To Our Newsletter & Stay Updated
